BCR and acute lymphoblastic leukemia: The number of gene mutation BCR–ABL positive patients taking tyrosine kinase inhibitors (TKIs), which are known to be critical factors for treatment outcomes of ALL, was similar between groups (nine people in the Asp-TPN group versus seven people in the control group; p = 0.78).